Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MS-553 MAD Study in Healthy Volunteers
NCT02406989Phase 1Completed
- Sponsor
- MingSight Pharmaceuticals
- Start
- Apr 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in diabetic retinopathy (DR), diabetic macular edema (DME) and chronic lymphocytic leukemia (CLL) comparing MS-553 with Placebo (2 arms). Primary endpoint: Number of Subjects with Adverse Events as a Measure of Safety and Tolerability at 14 days. Started Apr 2015; status: completed.
02
Drugs
MS-553
03
Conditions
diabetic retinopathy (DR)diabetic macular edema (DME)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02406989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02406989.